
Artisan Mid Cap Fund adds Guardant Health on screening growth
Artisan Partners cited rising testing volumes, adoption of Guardant’s Shield test and higher revenue guidance when adding the diagnostics company in the second quarter.
Event
Artisan Partners’ Artisan Mid Cap Fund added Guardant Health during the second quarter of 2026, citing its liquid biopsy diagnostics, cancer screening growth, rising testing volumes and raised revenue guidance.
2 published stories · markets · source reliability 33%

Artisan Partners cited rising testing volumes, adoption of Guardant’s Shield test and higher revenue guidance when adding the diagnostics company in the second quarter.
Background
Artisan Partners’ Artisan Mid Cap Fund added Guardant Health during Q2 2026. The fund cited Guardant’s liquid-biopsy diagnostics, accelerating adoption of its Shield colorectal-cancer screening test, rising testing volumes and increased full-year revenue guidance. Guardant provides blood and tissue tests and oncology-related data sets. The account is a secondary report of an investor letter, and the investment rationale is attributed to Artisan.
Artisan Partners’ Artisan Mid Cap Fund added Guardant Health during Q2 2026. The fund cited Guardant’s liquid-biopsy diagnostics, accelerating adoption of its Shield colorectal-cancer screening test, rising testing volumes and increased full-year revenue guidance. Guardant provid
Fact cards
Key entities: Guardant Health, Artisan Partners, Artisan Mid Cap Fund, Comfort Systems USA.
Why did Artisan add Guardant Health? It cited liquid-biopsy diagnostics, cancer-screening growth, rising testing volumes and raised revenue guidance. What is Guardant Health’s Shield test? It is a colorectal-cancer screening test whose adoption the fund said was accelerating. Wha
Yahoo Finance | https://finance.yahoo.com/markets/stocks/articles/makes-guardant-health-gh-compelling-132246436.html | published 2026-09-08T13:22:46.000Z | primary source | Yahoo Finance report, “What Makes Guardant Health (GH) a Compelling Bet?” | Secondary account of Artisan Mi
Q2 2026: Artisan Mid Cap Fund added Guardant Health. Q2 2026: The fund reported investor-class returns of 17.86%–17.93%, compared with 14.55% for the Russell Midcap Growth Index. End of Q2 2026: 80 hedge-fund portfolios reportedly held Guardant shares, up from 58 in the previous
Timeline
Artisan Mid Cap Fund added Guardant Health.
The fund reported investor-class returns of 17.86%–17.93%, compared with 14.55% for the Russell Midcap Growth Index.
80 hedge-fund portfolios reportedly held Guardant shares, up from 58 in the previous quarter.
Guardant closed at US$161.41, according to the report; its stated 52-week return was 168.28%.
Yahoo Finance published the secondary report.
FAQ
It cited liquid-biopsy diagnostics, cancer-screening growth, rising testing volumes and raised revenue guidance.
It is a colorectal-cancer screening test whose adoption the fund said was accelerating.
Blood and tissue tests and oncology-related data sets.
No. The rationale is attributed to Artisan Partners and reported second-hand.
The fund cited data centre construction demand, earnings growth, margin expansion and raised full-year guidance.
It provides heating, ventilation and air conditioning, mechanical and electrical installation, maintenance, repair and replacement services.
Artisan said hyperscaler-driven data centre construction accounted for a majority of revenue.
The available material does not specify the size, timing or purchase price.